Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 9/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.50 |
| ▸ | EIF4A1 | P60842 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29997485 | 0.94 | DHODH (0.60) | DHODHKDM4ESMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL23590091 | 0.94 | DHODH (0.60) | DHODHKDM4ESMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL23590289 | 0.94 | KDM4E (0.62) | DHODHKDM4ESMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL23590213 | 0.92 | DHODH (0.55) | DHODHKDM4ESMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL26074062 | 0.90 | KDM4E (0.58) | DHODHKDM4ESMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL29617652 | 0.89 | DHODH (0.71) | DHODHKDM4ESMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL23576327 | 0.89 | DHODH (0.71) | DHODHKDM4ESMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL23579655 | 0.89 | DHODH (0.58) | DHODHKDM4ESMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL23590238 | 0.88 | KDM4E (0.56) | DHODHKDM4ESMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL23579626 | 0.88 | DHODH (0.59) | DHODHKDM4ESMN1; SMN2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4438042-A2 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE | Ohio State Innovation Foundation (US) | 2024-10-02 | — | — | EP | disclosed |
| US-20240294477-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE | OHIO STATE INNOVATION FOUNDATION (US) | 2024-09-05 | — | — | US | disclosed |
| EP-3793562-B1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE | OHIO STATE INNOVATION FOUNDATION (US) | 2024-06-19 | — | — | EP | disclosed |
| US-11999697-B2 | Methods and compositions for inhibition of dihydroorotate dehydrogenase | OHIO STATE INNOVATION FOUNDATION (US) | 2024-06-04 | — | — | US | disclosed |
| US-20230303710-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT | OHIO STATE INNOVATION FOUNDATION (US) | 2023-09-28 | — | — | US | disclosed |
| WO-2023278778-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD47-SIRPΑ THERAPEUTIC AGENT | OHIO STATE INNOVATION FOUNDATION (US) | 2023-01-05 | — | — | WO | disclosed |
| US-11312686-B2 | Methods and compositions for inhibition of dihydroorotate dehydrogenase | OHIO STATE INNOVATION FOUNDATION (US) | 2022-04-26 | — | — | US | disclosed |
| US-11312686-B2 | Methods and compositions for inhibition of dihydroorotate dehydrogenase | OHIO STATE INNOVATION FOUNDATION (US) | 2022-04-26 | — | — | US | disclosed |
| US-20220064119-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE | HENDRIX COLLEGE | 2022-03-03 | — | — | US | disclosed |
| US-20210253531-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE | OHIO STATE INNOVATION FOUNDATION | 2021-08-19 | — | — | US | disclosed |
| WO-2021134045-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT | OHIO STATE INNOVATION FOUNDATION (US) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11312686-B2 | Methods and compositions for inhibition of dihydroorotate dehydrogenase | DHODH, DLD, DPYD | DHODH 1/4885KDM4E 474/4885SMN1; SMN2 3650/4885 |
| US-20230303710-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT | DHODH, CD38, DPYD | DHODH 1/4885KDM4E 1396/4885SMN1; SMN2 3677/4885 |
| US-20240294477-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE | DHODH, DLD, DPYD | DHODH 1/4885KDM4E 523/4885SMN1; SMN2 3708/4885 |
| US-20220064119-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE | DHODH, DLD, DPYD | DHODH 1/4885KDM4E 523/4885SMN1; SMN2 3708/4885 |
| US-20210253531-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE | DHODH, DLD, DPYD | DHODH 1/4885KDM4E 474/4885SMN1; SMN2 3650/4885 |
| US-11999697-B2 | Methods and compositions for inhibition of dihydroorotate dehydrogenase | DHODH, DLD, DPYD | DHODH 1/4885KDM4E 523/4885SMN1; SMN2 3708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.